Adrafinil vs Vinpocetine

Mechanism

Inactive prodrug that is hepatically metabolized to modafinil (via hepatic amidase enzymes) and its inactive acid metabolite modafinilic acid. The active metabolite modafinil then exerts its effects as a DAT inhibitor with downstream orexinergic, histaminergic, and noradrenergic activation. Conversion is incomplete — approximately 33-50% of adrafinil is converted to modafinil, with the remainder forming inactive metabolites. The hepatic first-pass metabolism means onset is delayed (60-90 minutes vs. 30-60 minutes for modafinil).

Standard Dosing

300-600 mg once daily (for educational context — unregulated prodrug of a prescription medication)

Timing

Early morning on an empty stomach for faster hepatic conversion. Onset delayed 60-90 minutes. Avoid afternoon/evening dosing due to long effective duration.

Cycle Duration

Short-term or intermittent use strongly preferred. Avoid continuous daily use exceeding 3 months without liver function monitoring.

Side Effects

• All modafinil side effects apply
• Elevated liver enzymes (ALT/AST)
• Potential hepatotoxicity with chronic use
• Skin reactions
• GI distress (more common than with modafinil due to hepatic metabolism)

Contraindications

• Hepatic impairment of any severity
• Concurrent hepatotoxic medication
• All contraindications for modafinil apply (cardiac conditions, anxiety disorders, pregnancy)
• History of liver disease or elevated liver enzymes

Best Stacking Partners

Mechanism

Semi-synthetic derivative of vincamine (from Vinca minor/periwinkle) that selectively inhibits phosphodiesterase type 1 (PDE1) in cerebral vasculature, increasing cAMP and cGMP levels to promote vasodilation and restore regional cerebral blood flow without significant systemic blood pressure effects. Reduces intracellular calcium in smooth muscle cells and neurons. Inhibits voltage-gated sodium channels, providing neuroprotection against excitotoxicity. Potent anti-inflammatory agent via direct inhibition of IKK, attenuating NF-kB signaling. Downstream CREB and SRF phosphorylation promotes expression of plasticity-related genes.

Standard Dosing

5-20 mg 2-3 times daily (15-60 mg/day total)

Timing

With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours).

Cycle Duration

Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks.

Side Effects

• Flushing
• GI distress
• Headache
• Dizziness
• Transient hypotension
• Sleep disturbance

Contraindications

• Severe hepatic impairment
• Pregnancy and lactation (FDA issued warning in 2019)
• Severe cardiac arrhythmias
• Recent hemorrhagic stroke

Best Stacking Partners